Fruchart, Jean-CharlesSantos, Raul DAguilar-Salinas, CarlosAikawa, MasanoriAl Rasadi, KhalidAmarenco, PierreBarter, Philip JCeska, RichardCorsini, AlbertoDesprés, Jean-PierreDuriez, PatrickEckel, Robert HEzhov, Marat VFarnier, MichelGinsberg, Henry NHermans, Michel PIshibashi, ShunKarpe, FredrikKodama, TatsuhikoKoenig, WolfgangKrempf, MichelLim, SooLorenzatti, Alberto JMcPherson, RuthNuñez-Cortes, Jesus MNordestgaard, Børge GOgawa, HisaoPackard, Chris JPlutzky, JorgePonte-Negretti, Carlos IPradhan, ArunaRay, Kausik KReiner, ŽeljkoRidker, Paul MRuscica, MassimilianoSadikot, ShaukatShimano, HitoshiSritara, PiyamitrStock, Jane KSu, Ta-ChenSusekov, Andrey VTartar, AndréTaskinen, Marja-RiittaTenenbaum, AlexanderTokgözoğlu, Lale STomlinson, BrianTybjærg-Hansen, AnneValensi, PaulVrablík, MichalWahli, WalterWatts, Gerald FYamashita, ShizuyaYokote, KoutaroZambon, AlbertoLibby, Peter2019-06-092019-06-092019-06-04Cardiovascular Diabetology. 2019 Jun 04;18(1):71https://doi.org/10.1186/s12933-019-0864-7https://doi.org/10.20381/ruor-23537http://hdl.handle.net/10393/39290Abstract In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.Journal Article2019-06-09enThe Author(s)